Literature DB >> 20924716

Duplication of Philadelphia chromosome and trisomy of chromosome 21 in a pediatric patient with acute lymphoblastic leukemia.

Katerina Katsibardi1, Maria Braoudaki, Stefanos I Papadhimitriou, Kalliopi Karamolegou, Fotini Tzortzatou-Stathopoulou.   

Abstract

The evaluation of molecular and cytogenetic characteristics using novel techniques has significantly contributed into the insight of leukemia. In this study, immunoglobulin heavy chain gene rearrangements (V(H)D(H)J(H) region) were analyzed by polymerase chain reaction (PCR). Point mutations of the D835/I836 in the activation loop (AL) domain of the second tyrosine kinase domain of the fms-related tyrosine kinase 3 (FLT3) gene and NRAS (neuroblastoma cell line) point mutations were also analyzed by PCR. Furthermore, sequence analysis of the V(H)D(H)J(H) region was performed, as well as, chromosomal aberrations were identified by interphase fluorescence in situ hybridization (iFISH) in a 12.5-year-old boy with acute lymphoblastic leukemia. Positive MRD was found in bone marrow samples obtained at various time points during and after treatment completion prior to relapse. Molecular analysis of the FLT3 gene mutations revealed an acquired a G → T mutation at codon 835, which resulted to substitution of aspartate 835 for tyrosine (D835Y). Cytogenetic analysis with iFISH showed t(9;22) (q34;q11.2), with minor-BCR/ABL1 fusion gene in the majority of nuclei, while a subclone with duplication of the Philadelphia chromosome was observed. Triple signals of AML1 were detected in 80% of nuclei, which were compatible with trisomy of chromosome 21. BCR/ABL1 fusion gene, duplication of Philadelphia chromosome and persistence of MRD constitute inferior prognostic factors, while hyperdiploidy, trisomy of chromosome 21 and FLT3-AL mutations are related to better prognosis. The study of cytogenetic and molecular characteristics is essential in order to decide on the optimal treatment protocol in childhood leukemia.

Entities:  

Mesh:

Year:  2010        PMID: 20924716     DOI: 10.1007/s12032-010-9689-7

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  10 in total

1.  FLT3 inhibition in t(4;11)+ adult acute lymphoid leukaemia.

Authors:  Giovanni F Torelli; Anna Guarini; Alessandra Porzia; Sabina Chiaretti; Caterina Tatarelli; Daniela Diverio; Roberta Maggio; Antonella Vitale; Jerome Ritz; Robin Foa
Journal:  Br J Haematol       Date:  2005-07       Impact factor: 6.998

2.  Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology/oncology unit.

Authors:  Katerina Katsibardi; Maria A Moschovi; Maria Braoudaki; Stefanos I Papadhimitriou; Chrissa Papathanasiou; Fotini Tzortzatou-Stathopoulou
Journal:  Leuk Lymphoma       Date:  2010-05

3.  Sequence of the human immunoglobulin diversity (D) segment locus: a systematic analysis provides no evidence for the use of DIR segments, inverted D segments, "minor" D segments or D-D recombination.

Authors:  S J Corbett; I M Tomlinson; E L Sonnhammer; D Buck; G Winter
Journal:  J Mol Biol       Date:  1997-07-25       Impact factor: 5.469

4.  Could intensified treatment in childhood acute lymphoblastic leukemia improve outcome independently of risk factors?

Authors:  Fotini Tzortzatou-Stathopoulou; Maria A Moschovi; Athina L Papadopoulou; Ioanna G Barbounaki; George I Lambrou; Myrsini Balafouta; Vassiliki Syriopoulou
Journal:  Eur J Haematol       Date:  2005-11       Impact factor: 2.997

5.  Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors.

Authors:  Panagiotis D Kottaridis; Rosemary E Gale; Stephen E Langabeer; Marion E Frew; David T Bowen; David C Linch
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

Review 6.  Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology.

Authors:  Giovanni Cazzaniga; Andrea Biondi
Journal:  Haematologica       Date:  2005-03       Impact factor: 9.941

7.  Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital.

Authors:  Ching-Hon Pui; John T Sandlund; Deqing Pei; Dario Campana; Gaston K Rivera; Raul C Ribeiro; Jeffrey E Rubnitz; Bassem I Razzouk; Scott C Howard; Melissa M Hudson; Cheng Cheng; Larry E Kun; Susana C Raimondi; Frederick G Behm; James R Downing; Mary V Relling; William E Evans
Journal:  Blood       Date:  2004-07-13       Impact factor: 22.113

8.  Frequency of FLT3 mutations in childhood acute lymphoblastic leukemia.

Authors:  M Braoudaki; M Karpusas; K Katsibardi; Ch Papathanassiou; K Karamolegou; F Tzortzatou-Stathopoulou
Journal:  Med Oncol       Date:  2008-12-16       Impact factor: 3.064

9.  Additional chromosomal abnormalities and variability of BCR breakpoints in Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia in Taiwan.

Authors:  Bor-Sheng Ko; Jih-Lu Tang; Fen-Yu Lee; Ming-Chi Liu; Woei Tsai; Yao-Chang Chen; Chiu-Hwa Wang; Ming-Chin Sheng; Dong-Tsam Lin; Kai-Hsin Lin; Hwei-Fang Tien
Journal:  Am J Hematol       Date:  2002-12       Impact factor: 10.047

10.  Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group Français de Cytogénétique Hématologique.

Authors: 
Journal:  Blood       Date:  1996-04-15       Impact factor: 22.113

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.